Millennium Management LLC Has $1.98 Million Stake in Vaxart, Inc. (NASDAQ:VXRT)

Millennium Management LLC lowered its position in shares of Vaxart, Inc. (NASDAQ:VXRT - Free Report) by 24.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,990,642 shares of the biotechnology company's stock after selling 978,449 shares during the quarter. Millennium Management LLC owned 1.31% of Vaxart worth $1,980,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of VXRT. Raymond James Financial Inc. acquired a new position in Vaxart during the fourth quarter valued at approximately $129,000. Sequoia Financial Advisors LLC grew its holdings in Vaxart by 140.9% during the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 35,213 shares during the period. Geode Capital Management LLC grew its holdings in Vaxart by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company's stock valued at $1,723,000 after purchasing an additional 57,911 shares during the period. Invesco Ltd. grew its holdings in Vaxart by 48.6% during the fourth quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 24,803 shares during the period. Finally, Silverarc Capital Management LLC grew its holdings in Vaxart by 7.8% during the fourth quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock valued at $714,000 after purchasing an additional 77,782 shares during the period. Institutional investors and hedge funds own 18.05% of the company's stock.

Insider Buying and Selling at Vaxart

In other Vaxart news, insider Steven Lo bought 100,000 shares of Vaxart stock in a transaction that occurred on Monday, May 19th. The stock was acquired at an average price of $0.49 per share, for a total transaction of $49,000.00. Following the completion of the acquisition, the insider now owns 100,000 shares of the company's stock, valued at $49,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 2.90% of the company's stock.

Wall Street Analysts Forecast Growth

VXRT has been the topic of a number of research reports. Wall Street Zen raised shares of Vaxart to a "hold" rating in a research note on Thursday, May 22nd. B. Riley cut their price target on shares of Vaxart from $2.50 to $2.00 and set a "buy" rating on the stock in a research note on Thursday, March 27th.

Vaxart Price Performance

VXRT traded down $0.01 during trading on Wednesday, reaching $0.40. The company had a trading volume of 1,889,230 shares, compared to its average volume of 2,438,424. Vaxart, Inc. has a 12 month low of $0.29 and a 12 month high of $1.07. The business's fifty day moving average price is $0.40 and its 200 day moving average price is $0.56. The company has a market cap of $92.20 million, a P/E ratio of -0.99 and a beta of 1.27.

Vaxart (NASDAQ:VXRT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.07). Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. The firm had revenue of $20.88 million for the quarter, compared to analyst estimates of $2.85 million. As a group, sell-side analysts predict that Vaxart, Inc. will post -0.39 EPS for the current fiscal year.

Vaxart Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.